Genocea Biosciences Inc GNCA Fundamentals and Key Ratios

Genocea Biosciences Inc. (GNCA) Fundamentals


Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

SHARE INFORMATION
Market Cap	$ 41,148
Shares Outstanding	58,783,503
Float	48,204,177
Percent Float	82.0%
Short Interest	1,637,397.00
Short Percent Float	2.8%
Short Interest Ratio	0.74
Short Interest Date	2022-05-13
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 1,641,000
Latest Fiscal EPS	$ -0.37
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	60
Institutional Holdings Date	2022-11-30
Institutional Bought Previous 3 Months	424,754
Institutional Holdings Percent	1.4%
Institutional Sold Previous 3 Months	8,155
Insider Holdings Date	2022-11-30
Insider Bought Previous 3 Months	-
Insider Holdings Percent	1.4
Insider Sold Previous 3 Months	-
Insider Shares Owned	793,985

TRADING INFO
52 Week High	$ 1.99
52 Week Low	$ 0.00
52 Week High Change	$ -99.56
21 Day Moving Average	$ 0.0112
21 Day Extended Moving Average	$ 0.011576
50 Day Moving Average	$ 0.0111
50 Day Extended Moving Average	$ 0.025652
200 Day Moving Average	$ 0.484807
200 Day Extended Moving Average	$ 0.48314
10 Day Average Volume	1,057,991
20 Day Average Volume	694,360
30 Day Average Volume	539,832
50 Day Average Volume	540,851
Alpha	-0.072838
Beta	1.7522
Standard Deviation	0.266671
R2	0.117381
7 Day Price Change	$ -0.0069
7 Day Percent Change	-46.31%
21 Day Price Change	$ -0.0019
21 Day Percent Change	-19.19%
30 Day Price Change	$ -0.0021
30 Day Percent Change	-20.79%
Month to Date Price Change	$ -0.0038
Month to Date Percent Change	-32.2%
Quarter to Date Price Change	$ -0.0038
Quarter to Date Percent Change	-32.2%
180 Day Price Change	$ -1.37
180 Day Percent Change	-99.42%
200 Day Price Change	$ -1.16
200 Day Percent Change	-99.32%
Year to Date Price Change	$ -1.15
Year to Date Percent Change	-99.31%

PROFITABILITY
EBIT Margin	-1,890.0%
EBITDA Margin	-1,807.5%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 270,000
Revenue Per Share	$ 0.0046
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	0.00
Total Debt To Equity	1.30
Int Coverage	-33.70
Current Ratio	1.40
Leverage Ratio	12.20
Quick Ratio	1.10
Long Term Debt To Capital	0.40

VALUATION MEASURES
PE Ratio	0.00
Enterprise Value	$ -4,422,745
Price to Sales	1.7417
Price to Free Cash	0.00
PE High Last 5 Years	-0.60
Price To Book	0.00
Price To Cash Flow	0.00
PE Low Last 5 Years	-0.80
Price to Tangible Book	0.00

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-63.01
Return on Equity	-529.45
Return on Capital	-146.59

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	Ernst & Young LLP
CEO	William D. Clark
Emplyoees	74
Last Audit	UE
CIK	0001457612
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	100 Acorn Park Drive Cambridge, MA 2140
Website	https://www.genocea.com
Facsimile	+1 617 500-0969
Telephone	+1 617 876-8191
Email	daniel@lifesciadvisors.com

Boards:

Quotes:

GNCA